Mylan N.V. is a global pharmaceutical company with a well-established generics business as well as a presence in specialty pharmaceuticals. The company’s business model includes the development, manufacturing and marketing of branded and generic drugs as well as active pharmaceutical ingredients (APIs) in North America, Europe and Rest of World. Notably, Mylan has one of the world’s largest API operations.
Mylan has been making prudent acquisitions and inking strategic deals to drive long-term growth. In Feb 2015, the company acquired Abbott Laboratories’ non-U.S. developed markets’ specialty and branded generics business. Further, in Nov 2015, it acquired certain female health care businesses of Famy Care.
However, Mylan has been under immense pressure since Aug 2016 when the company faced criticism for the price increase of EpiPen since its acquisition of the drug in 2007 from lawmakers, consumers and the common people alike.
Mylan’s performance has been decent so far, having beaten earnings estimates in three of the trailing four quarters and missing once. Overall, it has delivered an average positive surprise of 1.33%.
Currently, Mylan has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mylan missed on earnings. Our consensus called for EPS of $1.19, and the company reported EPS of $1.10.
Revenue: Revenues too missed expectations. Mylan posted revenues of $2.97 billion, compared to our consensus estimate of $3.00 billion.
Key Stats: Challenges in North America continue to impact performance. The company also lowered its guidance for 2017.
Pre-Market Trading: Shares are trading down on disappointing Q2 results.
Check back later for our full write up on this Mylan earnings report later!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Image: Bigstock
Mylan (MYL) Misses on Q2 Earnings & Revenues
Mylan N.V. is a global pharmaceutical company with a well-established generics business as well as a presence in specialty pharmaceuticals. The company’s business model includes the development, manufacturing and marketing of branded and generic drugs as well as active pharmaceutical ingredients (APIs) in North America, Europe and Rest of World. Notably, Mylan has one of the world’s largest API operations.
Mylan has been making prudent acquisitions and inking strategic deals to drive long-term growth. In Feb 2015, the company acquired Abbott Laboratories’ non-U.S. developed markets’ specialty and branded generics business. Further, in Nov 2015, it acquired certain female health care businesses of Famy Care.
However, Mylan has been under immense pressure since Aug 2016 when the company faced criticism for the price increase of EpiPen since its acquisition of the drug in 2007 from lawmakers, consumers and the common people alike.
Mylan’s performance has been decent so far, having beaten earnings estimates in three of the trailing four quarters and missing once. Overall, it has delivered an average positive surprise of 1.33%.
Currently, Mylan has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Mylan N.V. Price and EPS Surprise
Mylan N.V. Price and EPS Surprise | Mylan N.V. Quote
Earnings: Mylan missed on earnings. Our consensus called for EPS of $1.19, and the company reported EPS of $1.10.
Revenue: Revenues too missed expectations. Mylan posted revenues of $2.97 billion, compared to our consensus estimate of $3.00 billion.
Key Stats: Challenges in North America continue to impact performance. The company also lowered its guidance for 2017.
Pre-Market Trading: Shares are trading down on disappointing Q2 results.
Check back later for our full write up on this Mylan earnings report later!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>